Mark Pegram

15PUBLICATIONS

68CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingPredictive and prognostic markersCounselling, wellbeing and community services

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|Jul 09, 2026

Beyond amplification: precision approaches to targeting HER2.

|Dec 09, 2025

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Xiaosong Chen, Jiahui Huang, Haoting Shi

|Nov 14, 2025

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Nov 18, 2023

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.

Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam

|Jun 28, 2023

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.

Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac

|May 31, 2023

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.

Mark Pegram, Christian Jackisch, Stephen R D Johnston

Pageof 3

Frequent Collaborators

Nancy U Lin

Nuhad Ibrahim

William J Gradishar

Whitney Kirschbrown

Seth A Wander

Peter A Fasching

Hope S Rugo

A C Matin

Nabeel Attarwala

Yun-Sheng Chen

Frequent Collaborators

Nancy U Lin

Nuhad Ibrahim

William J Gradishar

Whitney Kirschbrown